Group 1 - The core viewpoint of the news is that Hongbo Pharmaceutical's stock has increased by 5.14%, reaching a price of 48.85 CNY per share, with a trading volume of 503 million CNY and a turnover rate of 8.46%, resulting in a total market capitalization of 6.819 billion CNY [1] - Hongbo Pharmaceutical, established on December 14, 2007, and listed on November 1, 2022, is located in Shanghai and focuses on drug discovery, pharmaceutical process research and development, and the commercial production of active pharmaceutical ingredients. The revenue composition is as follows: drug discovery 52.67%, commercial production 35.00%, process research and development 8.10%, and others 4.23% [1] Group 2 - Longcheng Fund's Longcheng Consumption Value Mixed A Fund (200006) is among the top ten circulating shareholders of Hongbo Pharmaceutical, holding 1.6009 million shares, unchanged from the previous period, representing 2.08% of circulating shares, with an estimated floating profit of approximately 3.8262 million CNY [2] - The Longcheng Consumption Value Mixed A Fund has a total scale of 474 million CNY, with a year-to-date return of 8.38%, ranking 925 out of 8874 in its category, and a one-year return of 26.19%, ranking 4175 out of 8124 [2] Group 3 - The fund manager of Longcheng Consumption Value Mixed A Fund is Long Yufei, who has been in the position for 8 years and 111 days, managing assets totaling 704 million CNY, with the best fund return during his tenure being 61.42% and the worst being -8.9% [3] Group 4 - Longcheng Consumption Value Mixed A Fund reduced its holdings in Hongbo Pharmaceutical by 100,000 shares in the fourth quarter, now holding 1.5009 million shares, which accounts for 6.37% of the fund's net value, making it the sixth-largest holding [4]

Group 1 - The core viewpoint of the news is that Hongbo Pharmaceutical has shown significant financial performance and trading activity, with a notable increase in revenue and net profit year-on-year [1][2][3] Group 2 - As of January 26, Hongbo Pharmaceutical's stock price increased by 1.64%, with a trading volume of 928 million yuan [1] - The financing buy-in amount on January 26 was 91.54 million yuan, while the financing repayment was 83.11 million yuan, resulting in a net financing buy of 8.42 million yuan [1] - The total balance of margin trading for Hongbo Pharmaceutical reached 388 million yuan, with the financing balance accounting for 5.53% of the circulating market value, indicating a high level compared to the past year [1] Group 3 - For the fiscal year ending September 30, 2025, Hongbo Pharmaceutical achieved an operating income of 514 million yuan, representing a year-on-year growth of 31.43% [2] - The net profit attributable to the parent company was approximately 34.75 million yuan, reflecting a substantial increase of 127.96% compared to the previous year [2] Group 4 - Since its A-share listing, Hongbo Pharmaceutical has distributed a total of 156 million yuan in dividends [3] - As of September 30, 2025, the number of shareholders was 14,000, a decrease of 1.34% from the previous period, while the average circulating shares per person increased by 1.36% to 8,960 shares [2][3]